Genomics-based analyses have provided deep insight into the basic biology of cancer and are now clarifying the molecular pathways by which psychological and social factors can regulate tumor cell gene expression and genome evolution. This review summarizes basic and clinical research on neural and endocrine regulation of the cancer genome and its interactions with the surrounding tumor microenvironment, including the specific types of genes subject to neural and endocrine regulation, the signal transduction pathways that mediate such effects, and therapeutic approaches that might be deployed to mitigate their impact. Beta-adrenergic signaling from the sympathetic nervous system has been found to up-regulated a diverse array of genes that contribute to tumor progression and metastasis, whereas glucocorticoid-regulated genes can inhibit DNA repair and promote cancer cell survival and resistance to chemotherapy. Relationships between socio-environmental risk factors, neural and endocrine signaling to the tumor microenvironment, and transcriptional responses by cancer cells and surrounding stromal cells are providing new mechanistic insights into the social epidemiology of cancer, new therapeutic approaches for protecting the health of cancer patients, and new molecular biomarkers for assessing the impact of behavioral and pharmacologic interventions.
Introduction
Cancer is fundamentally a disease of dysregulated gene function that originates from structural genomic damage such as chromosomal amplifications, deletions, mutations, and rearrangements. The biological consequences of that structural genomic damage in cancer cells interacts with dysregulated expression of physiologic genes in neighboring healthy ''stromal'' cells to facilitate the unchecked growth and survival of cancer cells and their metastatic dissemination to distant tissues (Hanahan and Weinberg, 2011; Kinzler and Vogelstein, 1998, 2004) . The development of highthroughput molecular technologies for mapping the structure of the human genome (e.g., ''next generation'' DNA sequencing) and quantifying the expression of all 21,000 human genes (e.g., RNA sequencing and gene expression microarrays) has revolutionized cancer biology. Molecular genetics now constitutes the primary paradigm through which cancer is understood as a biological phenomenon, and genomics-based analyses are playing an increasingly prominent role in clinical cancer diagnosis and treatment selection (Kim and Paik, 2010) , and in mapping the molecular lesions that cause cancer (Tomlins et al., 2005) . In this review, we consider another domain in which genomics-based approaches have begun to revolutionize our understanding of cancer -in mapping the biological pathways by which patient-level social and psychological processes can influence the development, progression, and treatment of cancer. The human genome has evolved a broad transcriptional sensitivity to hormones and neurotransmitters that convey information from the social and psychological realm into molecular biological alterations that help the body respond to both current and anticipated homeostatic challenges (Cole, 2009). As pathological derivatives of normal human cells, cancer cells are also sensitive to neural and endocrine regulation, as are the surrounding immune cells, blood vessels, and other stromal cells that interact with tumor cells within the ''tumor microenvironment '' (Antoni et al., 2006) . Thus, the same gene regulatory programs that allow social and psychological processes to modulate healthy human genome function can also modulate the altered cancer genome, and thereby influence the development and progression of neoplastic disease.
Social and psychological regulation of the human genome

Gene programs
The potential for psychosocial regulation of human gene expression first emerged in the context of studies analyzing the
